Other news to note for April 14, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Applied Biology, Arcturus, Astrazeneca, Avacta, Aytu, Biogen, Biontech, Biosig, Celltrion, Celularity, Chromocell, CSL Behring, Cytodyn, Cytovia, Danaher, Enlivex, Epivax, Excelra, Flow, Gilead, Glaxosmithkline, Hitgen, Ilias, Immunomic, Immutep, Intellistem, Iqvia, Karyopharm, La Jolla, Macromoltek, Mateon, Medgenome, Medicinova, Mitsubishi Tanabe, Neurorx, Novacyt, Ossianix, Pfizer, Pharmacyte, Pharmajet, Pharmazz, Pluristem, Recce, Redhill, Regeneron, Relief, Reneuron, Revive, Samsung Biologics, Sanofi, Theravance, Thermogenesis, Vanda, Vaxil, Vir, Wuxi, Zai Lab.

Regulatory front for April 14, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Drug Enforcement Administration, Department of Health and Human Services, FDA, International Coalition of Medicines Regulatory Authorities, EMA, European Commission, National Institute for Health and Care Excellence, NIH, Office for Human Research Protections, Pharmaceuticals and Medical Devices Agency, Therapeutic Goods Administration.

Clinical data for April 7-13, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aslan, Bausch Health, Biocryst, Bridge, Eli Lilly, Firstwave, Fujifilm, Kazia, Laurent, Mesoblast, Neuclone, Viriom.

Regulatory actions for April 7-13, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Algernon, Arcturus, Ascentage, Ascletis, Astellas, Athersys, Beigene, Bellerophon, Biohaven, Calcimedica, Can-Fite, Hope, Predictive, Ridgeback.

No Comments